24.40

1.69% -0.42

Denali Therapeutics Inc (DNLI)

Overview News Price History Option Chain Financials Why DNLI Down? Discussions Forecast

Denali Therapeutics Inc stock is traded at $24.40, with a volume of 876.21K. It is down -1.69% in the last 24 hours and up +7.73% over the past month. Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Previous Close:

$24.82

Open:

$24.53

24h Volume:

876.21K

Relative Volume:

0.49

Market Cap:

$3.90B

Revenue:

$1.27M

Net Income/Loss:

$-508.02M

P/E Ratio:

-8.4702

EPS:

-2.8807

Net Cash Flow:

$-419.23M

1W Performance:

-1.73%

1M Performance:

+7.73%

6M Performance:

+29.99%

1Y Performance:

+68.74%

1-Day Range:

$24.11

$24.62

1-Week Range:

$24.11

$25.64

52-Week Range:

$12.58

$27.30

Denali Therapeutics Inc Stock (DNLI) Company Profile

Name

Denali Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(650) 866-8547

Address

161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO

Employee

507

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

DNLI's Discussions on Twitter

Compare DNLI vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNLI Denali Therapeutics Inc	24.40	4.04B	1.27M	-508.02M	-419.23M	-2.8807
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Reiterated	H.C. Wainwright	Buy
Feb-24-26	Initiated	Wolfe Research	Peer Perform
Jan-07-26	Resumed	UBS	Buy
Apr-10-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-07-25	Resumed	Morgan Stanley	Overweight
Feb-11-25	Initiated	Deutsche Bank	Buy
Jan-07-25	Initiated	Robert W. Baird	Outperform
Jan-03-25	Initiated	William Blair	Outperform
Dec-16-24	Upgrade	Stifel	Hold → Buy
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-07-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-13-23	Initiated	Citigroup	Buy
Nov-20-23	Resumed	JP Morgan	Overweight
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Sep-06-23	Initiated	B. Riley Securities	Buy
Jan-30-23	Initiated	SVB Securities	Outperform
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy
Nov-02-22	Initiated	BofA Securities	Buy
Jun-23-22	Initiated	Berenberg	Buy
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform
Sep-01-21	Initiated	SMBC Nikko	Outperform
May-18-21	Initiated	UBS	Buy
Feb-26-21	Reiterated	H.C. Wainwright	Buy
Feb-10-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-11-20	Reiterated	H.C. Wainwright	Buy
Oct-16-20	Downgrade	BTIG Research	Buy → Neutral
Sep-14-20	Resumed	JP Morgan	Overweight
Aug-20-20	Reiterated	H.C. Wainwright	Buy
Mar-13-20	Upgrade	Evercore ISI	In-line → Outperform
Feb-28-20	Upgrade	Wedbush	Neutral → Outperform
Feb-24-20	Initiated	Jefferies	Buy
Feb-19-20	Initiated	Stifel	Hold
Jan-27-20	Upgrade	Goldman	Neutral → Buy
Sep-26-19	Initiated	Wedbush	Neutral
Sep-13-19	Initiated	Nomura	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-26-19	Initiated	H.C. Wainwright	Buy
Nov-15-18	Initiated	Cantor Fitzgerald	Overweight
Nov-12-18	Initiated	Janney	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Jan-02-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Initiated	Goldman	Neutral
Jan-02-18	Initiated	JP Morgan	Overweight
Jan-02-18	Initiated	Morgan Stanley	Overweight

View All

Denali Therapeutics Inc Stock (DNLI) Latest News

Aug 14, 2026

Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund - Kalkine Media

Aug 14, 2026

Aug 13, 2026

Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock - MarketBeat

Aug 13, 2026

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 13, 2026

Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One (NASDAQ:DNLI) - Seeking Alpha

Aug 13, 2026

Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI - MarketBeat

Aug 13, 2026

Aug 11, 2026

J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - Moomoo

Aug 11, 2026

Equities Analysts Set Expectations for DNLI Q3 Earnings - MarketBeat

Aug 11, 2026

E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI - MarketBeat

Aug 11, 2026

Aug 10, 2026

Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction - GuruFocus

Aug 10, 2026

Weekly Recap: Q2 revenue, big net loss and DNL126 Phase 3 with 2027 BLA - TradingView

Aug 10, 2026

Denali climbs past Avlayah expectations with $3.6M in revenue - BioSpace

Aug 10, 2026

Aug 09, 2026

(DNLI) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Aug 09, 2026

The Manufacturers Life Insurance Company Lowers Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat

Aug 09, 2026

Aug 08, 2026

Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat

Aug 08, 2026

A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo

Aug 08, 2026

Denali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue - Sahm

Aug 08, 2026

Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Aug 08, 2026

Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Aug 08, 2026

Aug 07, 2026

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - Yahoo Finance

Aug 07, 2026

UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating - marketscreener.com

Aug 07, 2026

Denali Therapeutics Inc. Stock 12‑Month Price Target Raised to $35.44, Implies 43% Upside - TradingView

Aug 07, 2026

A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $41 - Moomoo

Aug 07, 2026

Denali Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 07, 2026

Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating - marketscreener.com

Aug 07, 2026

Earnings call transcript: Denali Therapeutics posts Q2 2026 revenue miss as AVLAYAH launch builds - Investing.com Nigeria

Aug 07, 2026

Denali Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:DNLI) 2026-08-07 - Seeking Alpha

Aug 07, 2026

Denali Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com

Aug 06, 2026

Denali Q2 2026 earnings: AVLAYAH debuts with $3.6 million in revenue - TradingKey

Aug 06, 2026